ArticleAnnals of clinical and translational neurology2023
Clinical features and brain MRI volumetric changes in anti-mGluR5 encephalitis.
Article in Annals of clinical and translational neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.
- Clinical features of anti-mGluR5 encephalitis and comparison according to MRI positivity: a systematic review and analysis.Frontiers in immunology · 2026Pooled it
- Anti-mGluR5 encephalitis: distinctive clinical features and antibody patterns in the Chinese population.Frontiers in immunology · 2026Pooled it
- Suspected encephalitis in adults.Practical neurology · 2026Review
- Neuronal antibody targeting metabotropic glutamate receptor 8 in five cases and its pathogenicity.Journal of neurology · 2026Article
- Triple antibody-associated autoimmune encephalitis overlap: a case report of co-existing MOG-IgG, anti-NMDAR, and anti-mGluR5 positivity.Frontiers in immunology · 2026Article
- Spontaneous partial resolution of autoimmune-mediated brain MRI abnormalities before immunotherapy in anti-metabotropic glutamate receptor 5 encephalitis: a case report.Frontiers in immunology · 2025Article
- Clinical spectrum and outcomes of anti-metabotropic glutamate receptor 5 encephalitis in Chinese patients: a case report and literature review.Frontiers in immunology · 2025Review
- Anti-metabotropic glutamate receptor 5 coexistent anti-N-methyl-D-aspartate receptor encephalitis: a case report and literature review.Frontiers in immunology · 2025Review
- mGlur5 Encephalitis Causing Myoclonus-Ataxia Syndrome and Psychosis: A Case Report.Movement disorders clinical practice · 2024Article
- Decoding Dystonia in Autoimmune Disorders: A Scoping Review.Tremor and other hyperkinetic movements (New York, N.Y.) · 2024Article
- Persisting Verbal Memory Encoding and Recall Deficiency after mGluR5 Autoantibody-Mediated Encephalitis.Brain sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnti-metabotropic glutamate receptor 5 (mGluR5) encephalitis is a rare and under-recognized autoimmune encephalitis. This study is conducted to characterize its clinical and neuroimaging features.
methodsTwenty-nine patients with anti-mGluR5 encephalitis (15 new cases identified in this study and 14 previously reported cases) were included in this study and their clinical features were characterized. Brain MRI volumetric analysis using FreeSurfer software was performed in 9 new patients and compared with 25 healthy controls at both early (≤6 months of onset) and chronic (>1 year of onset) disease stages.
resultsThe common clinical manifestations of anti-mGluR5 encephalitis included cognitive deficits (n = 21, 72.4%), behavioral and mood disturbances (n = 20, 69%), seizures (n = 16, 55.2%), and sleep disorder (n = 13, 44.8%). Tumors were observed in 7 patients. Brain MRI T2/FLAIR signal hyperintensities were observed predominantly in mesiotemporal and subcortical regions in 75.9% patients. MRI volumetric analysis demonstrated significant amygdala enlargement in both early and chronic disease stages compared to healthy controls (P < 0.001). Twenty-six patients had complete or partial recovery, one remained stable, one died and one was lost to follow-up.
conclusionOur findings demonstrated that cognitive impairment, behavioral disturbance, seizures, and sleep disorder are the prominent clinical manifestations of anti-mGluR5 encephalitis. Most patients showed a good prognosis with full recovery, even in the paraneoplastic disease variants. The amygdala enlargement in the early and chronic disease stages is a distinct MRI feature, which exploratively offer a valuable perspective for the study of the disease processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.